Cytochrome P450 3A-Mediated Microsomal Biotransformation of 1α,25-Dihydroxyvitamin D₃ in Mouse and Human Liver: Drug-Related Induction and Inhibition of Catabolism

Subrata Deb,¹ Mitali Pandey, Hans Adomat, and Emma S. Tomlinson Guns

The Vancouver Prostate Centre at Vancouver General Hospital, Vancouver, British Columbia, Canada

Received July 12, 2011; accepted February 2, 2012

ABSTRACT:

The biological activities of vitamin D₃ are exerted through the dihydroxy metabolite of vitamin D₃ [1α,25(OH)₂D₃]. Hepatic biotransformation of 1α,25(OH)₂D₃ by cytochrome P450 (P450) enzymes could be an important determinant of bioavailability in serum and tissues. In the present study, we investigated the comparative biotransformation of 1α,25(OH)₂D₃ in mouse and human liver microsomes and determined the effects of commonly used drugs on the catabolism of 1α,25(OH)₂D₃. Severe symptoms of vitamin D deficiency have historically been observed in patients who received dexamethasone. To compare the effects of clinically important glucocorticoids with hepatic biotransformation of 1α,25(OH)₂D₃, adult male CD-1 mice were given intraperitoneal injections of either vehicle (50% ethanol), dexamethasone (80 mg/kg per day), or prednisone (80 mg/kg per day) for three consecutive days. Hydroxy metabolite formation pattern and the extent of substrate depletion were similar in mouse liver microsomes (MLM) from vehicle- or prednisone-treated mice, whereas treatment with dexamethasone led to the emergence of additional metabolites and increased substrate depletion, as determined by liquid chromatography/mass spectrometry. The metabolite formation profile in vehicle-treated mice was different from that of human liver microsomes (HLM). Selective P450 chemical inhibitors have demonstrated that CYP3A isoforms are responsible for the microsomal biotransformation of 1α,25(OH)₂D₃ in MLM. Coincubation of 1α,25(OH)₂D₃ with commonly used drugs led to approximately 60 to 100% inhibition of CYP3A-mediated catabolism of 1α,25(OH)₂D₃ in HLM. A species-based difference was identified between CYP3A-mediated hepatic microsomal metabolism of 1α,25(OH)₂D₃ in humans and mice. We have shown that the clinical importance of glucocorticoids differentially modulates catabolism of active vitamin D₃ and that commonly used drugs could affect vitamin D homeostasis.

Introduction

Epidemiological studies have shown that lower serum levels of vitamin D₃ are associated with increased risk of prostate, colon, and breast cancer (Garland et al., 2009). The biological activities of vitamin D₃ are attributed to 1α,25-dihydroxyvitamin D₃ [1α,25(OH)₂D₃], which acts primarily by binding to the vitamin D receptor (VDR) (Deeb et al., 2007). 1α,25(OH)₂D₃ shows antiproliferative, prodifferentiation, and antiangiogenic effects in both human prostate cancer cells in vitro and preclinical animal studies (Deeb et al., 2007). In addition, preliminary clinical investigations have reported a promising antitumor role of 1α,25(OH)₂D₃. For example, cotreatment of advanced prostate cancer patients with taxanes (e.g., paclitaxel, docetaxel) and 1α,25(OH)₂D₃ was shown to potentiate cytotoxic effects and/or increase the survival rates compared with treatment with only taxanes or placebo (Munindi et al., 2002; Beer et al., 2007). In addition, AIDS patients have lower vitamin D₃ levels (Dao et al., 2011), which may render them susceptible to further lowering of immune function, bone diseases, and increased risk of opportunistic infections. Vitamin D₃ and its derivatives have been successfully used in the treatment of autoimmune skin diseases such as psoriasis and vitiligo (Signon et al., 2009).

In vertebrates, vitamin D₃ is synthesized from 7-dehydrocholesterol in the skin through exposure to UVB radiation or can be obtained from dietary sources (Deeb et al., 2007). Serum proteins transport vitamin D₃ to the liver, where multiple cytochrome P450 (P450) enzymes in mitochondria (e.g., CYP27A1) and microsomes (e.g., CYP2J3 and CYP2R1) are capable of hydroxylating it at the C-25 position (Prosser and Jones, 2004; Ingraham et al., 2008). The serum 25(OH)D₃ has gained some acceptance as a measure of vitamin D₃ in the body (Schuster, 2011). In response to low calcium levels, renal
CYP27B1 catalyzes the 1α-hydroxylation of 25(OH)D3 to form 1α,25(OH)2D3, which is a small lipophilic molecule with superior cellular penetration and is the most potent endogenous agonist of VDR (Ingram et al., 2008). Subsequently, 1α,25(OH)2D3 is converted to inactive metabolites by mitochondrial CYP24A1 in kidney (Schuster, 2011).

Epidemiological and clinical reports show that patients on certain classes of medications, such as antiepileptics (e.g., carbamazepine and phenytoin) and protease inhibitors (e.g., efavirenz), experience lower vitamin D levels, reduced calcium absorption, and impaired bone health (Verrotti et al., 2010). Likewise, vitamin D deficiency-like phenotypes were observed in patients who received dexamethasone, a commonly used anti-inflammatory glucocorticoid steroid with adverse effects on bone health (Reid and Heap, 1990). In contrast, prednisone, which is also an anti-inflammatory glucocorticoid steroid with adverse effects on bone health (Reid and Heap, 1990), is less potent than dexamethasone in repressing markers for bone formation (e.g., osteocalcin) as well as overall bone health (e.g., bone fracture, osteopenia, osteonecrosis) (Dubois et al., 2003; Inaba and Pui, 2010). There is no experimental evidence to define the effects of glucocorticoids on biotransformation of biologically active 1α,25(OH)2D3. In addition, a lack of studies present challenges for the direct comparison of dexamethasone- and prednisone-mediated negative effects on vitamin D status and bone health.

1α,25(OH)2D3 works as a paracrine and as an autocrine agent via VDR-mediated mechanisms (Morris and Anderson, 2010). Thus, catalysation of 1α,25(OH)2D3 in the liver could have a significant impact on VDR response. CYP3A4 is the major hepatic phase I oxidative drug-metabolizing enzyme with broad substrate specificity and is inducible after exposure to therapeutic, dietary, and environmental agents (Thummel and Wilkinson, 1998). Gupta et al. (2004, 2005) reported that CYP3A4 mediates 24- and 25-hydroxylation activity of 1α(OH)D3, but not vitamin D3, in human liver microsomes (HLM). Hepatic biotransformation of 1α,25(OH)2D3 by P450 enzymes may influence its circulating serum and tissue levels. Xu et al. (2006) reported on the hepatic metabolism of 1α,25(OH)2D3 in humans; however, there is no report of 1α,25(OH)2D3 biotransformation in mice, despite the fact that it is a widely used animal model in vitamin D research. Our study investigates the comparative biotransformation of 1α,25(OH)2D3 to its inactive hydroxy metabolites in mouse liver microsomes (MLM) and HLM. In addition, we have sought to determine the effects of various medications, which are commonly used in the treatment regimens of patients with cancer (e.g., ketoconazole, tamoxifen, taxanes), AIDS (e.g., ritonavir, clarithromycin), as well as inflammatory disorders (e.g., dexamethasone, prednisone), on hepatic biotransformation of 1α,25(OH)2D3.

Materials and Methods

Chemicals. 1α,25(OH)2D3, 25(OH)D3, dexamethasone sodium, prednisone, α-naphthoflavone, furafylline, sulfaphenazole, 8-methoxypsoralen, orphenadrine, quinine, 2-diethylaminoethyl 2,2-diphenylvalerate hydrochloride (SKF 525A), sodium diethyldithiocarbamate, docetaxel, paclitaxel, chloramphenicol, and clarithromycin were obtained from Sigma-Aldrich Canada Ltd. (Oakville, ON, Canada). Ritonavir and troleandomycin were purchased from Toronto Research Chemicals (North York, ON, Canada) and Enzo Life Sciences International, Inc. (Plymouth Meeting, PA), respectively. Ketoconazole and tamoxifen were obtained from MP Biomedical, LLC (Solon, OH). Pooled HLM of mixed gender were purchased from XenoTech, LLC (Lenexa, KS).

Animal Treatment and Preparation of Liver Microsomes. Adult male CD-1 mice were obtained from Harlan Laboratories Inc. (Montreal, QC, Canada). Mice were housed in polycarbonate cages with corn-cob bedding at a temperature of 20–23°C and had a 12-h photoperiod. Mice were given commercial mouse diet and water ad libitum. Mice were cared for and treated in accordance with the principles and guidelines of the Canadian Council on Animal Care.

Mice were treated with dexamethasone or prednisone dissolved in 50% ethanol at a dosage of 80 mg/kg b.w.t. or an equivalent volume of vehicle (three mice per group) by intraperitoneal injection once a day, for three consecutive days. Mice were euthanized 24 h after the last dose, and livers were immediately excised and were used for preparation of microsomes by differential ultracentrifugation. Microsomal pellets were suspended in 0.25 M sucrose, and aliquots were stored at −80°C until needed. Total protein concentration in each microsomal sample was determined by the bicinchoninic acid (Thermo Fisher Scientific, Waltham, MA) assay using bovine serum albumin as the protein standard.

1α,25(OH)2D3 Biotransformation Assay. In vitro reaction mixtures contained 100 mM potassium phosphate buffer (pH 7.4), mouse hepatic microsomal protein (0.15 mg/ml) or human hepatic microsomal protein (0.25 mg/ml), or human recombinant CYP3A4 (rCYP3A4) Supremes (15 pmol/ml), NADPH-regenerating system (solution A and B), and varying concentrations of 1α,25(OH)2D3 (2–40 μM) in a final volume of 0.3 ml. A fixed concentration of 20 μM 1α,25(OH)2D3 was used to compare the treated samples, and this concentration was also used in the inhibition studies. For the substrate depletion study, 1α,25(OH)2D3 was incubated with hepatic microsomes from vehicle-, dexamethasone-, or prednisone-treated mice at a concentration of 1 μM. After an initial preincubation at 37°C for 10 min, the reaction was initiated by adding saturating concentrations of NADPH and was allowed to proceed for 30 min in a shaking water bath. The reaction was terminated with 900 μl of ice-cold acetonitrile. Protopanaxatriol (0.5 μg/ml) was used as an internal standard in the assay. Tubes were vortex-mixed for 1 min and centrifuged at 12,000 rpm for 5 min at 4°C. Supernatant was transferred, a clean Eppendorf tube and dried down using a CentriVap centrifugal evaporation system (35°C). Samples were then reconstituted in 100 μl of methanol, and an aliquot was injected into the liquid chromatography/mass spectrometry (LC/MS).

The assay conditions were optimized to ensure that product formation was linear with respect to amount of protein and incubation time. Appropriate controls, including samples without substrate, microsomes or NADPH, were routinely used in the assay. For the study using human rCYP3A4, control samples contained insect cell microsomes or P450 reductase (plus cytochrome b5) microsomes instead of CYP3A4 protein.

A Waters Acuity ultraperformance liquid chromatography (UPLC) system (Waters, Milford, MA) coupled to a Quattro Premier XE (Waters) triple quadrupole mass spectrometer (MS) was used for analysis of hydroxy metabolite formation of 1α,25(OH)2D3 and substrate depletion. Chromatographic separations of hydroxy metabolites of 1α,25(OH)2D3 were performed on a Waters Acuity UPLC BEH C18 column (2.1 × 100 mm, 1.7 μm) at 40°C with a flow rate maintained at 0.3 ml/min and total run time of 20 min. The mobile phase consisted of solvent A (water/2 mM ammonium acetate/0.1%
formic acid) and solvent B (methanol/2 mM ammonium acetate/0.1% formic acid) with the following conditions: 50% methanol (0–0.2 min), followed by a gradient of 50–100% methanol (0.2–15 min), isocratic elution with 100% methanol (12–20 min), and finally 50% methanol (17–20 min). The LC eluant was introduced into the MS, and all data were collected in electrospray ionization positive mode with a capillary voltage of 3.2 kV. Source and desolvation temperatures were 120°C and 350°C, respectively, and Ne gas flow was 1000 l/h. MassLynx version 4.1 software was used for data acquisition and QuantLynx analyses. The quantitative determination of 1α,25(OH)2D3 metabolites was performed by multiple reaction monitoring of the m/z 450 > 397 transition using cation voltage of 25 V and collision energy of 10 eV.

Data Analysis and Calculation of Enzyme Kinetic Parameters. Enzyme kinetic parameters ($K_m$ and $V_{max}$) were determined using the SigmaPlot Enzyme Kinetics Module (version 1.3; Systat Software, Inc., San Jose, CA). Nonlinear regression analysis was used to study the metabolism of vitamin D3 in response to a range of substrate concentrations. The Michaelis-Menten enzyme kinetic analysis was performed with GraphPad Prism 5 (GraphPad Software Inc., San Diego, CA). Determination of IC$_{50}$ values was performed by non-linear regression analysis using GraphPad Prism 5 (GraphPad Software Inc., San Diego, CA). The IC$_{50}$ values are expressed as means with associated 95% confidence limits in parenthesis.

Results

Metabolism of 1α,25(OH)2D3 by Human and Mouse Liver Microsomes and Human Recombinant CYP3A4. An LC/MS-based in vitro biotransformation assay was optimized to study the metabolism of 1α,25(OH)2D3. Hydroxy metabolites of 1α,25(OH)2D3 were identified by comparing their retention times and m/z with those of authentic standards. Authentic metabolite standards of 1α,24R,25-trihydroxyvitamin D$_3$ [1α,24R,25(OH)2D$_3$] and 1α,23S,25-trihydroxyvitamin D$_3$ [1α,23S,25(OH)2D$_3$] were a kind gift from Dr. Toshiyuki Sakaki (Toyama Prefectural University, Toyama, Japan). Incubation of 1α,25(OH)2D3 with pooled HLM led to formation of four monohydroxy metabolites, M1 to M4 (Fig. 1A). In the present experimental conditions, metabolites eluted between 8.5 to 9.7 min.

In the internal standard and substrate eluted at 8.8 and 10.9 min, respectively. Metabolite peaks corresponding to 1α,23S,25(OH)2D$_3$ (M1) and 1α,24R,25(OH)2D$_3$ (M2) were eluted at 8.5 and 8.8 min, respectively (Supplemental Fig. 1). M3 and M4 hydroxy metabolites resolved at 9 and 9.7 min. From data showing relative abundance of ions, we can suggest that M4 was the major metabolite, whereas M1, M2, and M3 were formed in lesser amounts in HLM incubations. An identical metabolite formation pattern was observed after incubation of 1α,25(OH)2D3 with human rCYP3A4 Supersomes. No metabolite formation was detected in reaction mixtures without substrate, NADPH, or microsomes.

In contrast, incubation of 1α,25(OH)2D3 with hepatic microsomes from vehicle- or prednisone-treated mice yielded one major metabolite at 8.9 min (M5) in addition to 1α,23S,25(OH)2D$_3$ (M1) and 1α,24R,25(OH)2D$_3$ (M2) as minor metabolites (Fig. 1B).
the metabolite profile determined in HLM, dexamethasone-treated mice yielded four metabolites, M1 to M4. However, unlike HLM, M4 was a minor metabolite, whereas, M1, M2, and M3 were the major metabolites formed in the hepatic microsomes prepared from dexamethasone-treated mice.

**Effect of Treatment with Glucocorticoids on 1α,25(OH)2D3 Metabolism.** To investigate the effects of treatment with glucocorticoids, experiments were performed with hepatic microsomes prepared from male CD-1 mice treated with vehicle, dexamethasone, or prednisone. The formation of 1α,23S,25(OH)2D3 (M1) and 1α,24R,25(OH)2D3 (M2) was significantly stimulated (43- and 17-fold, respectively) in dexamethasone-treated mice compared with the vehicle-treated group (Fig. 2A). Metabolites M3 and M4 were detectable only in hepatic microsomes from dexamethasone-treated mice but not in vehicle- or prednisone-treated mice (Fig. 2B). In contrast, treatment with prednisone led to very little or no change in the formation of M1 and M2 metabolites (Fig. 2A) and a marginal increase in M5 formation compared with vehicle-treated mice (Fig. 2C). In the substrate-depletion study, there was a 70% greater loss of 1α,25(OH)2D3 after incubation with hepatic microsomes from dexamethasone-treated mice compared with vehicle-treated mice. In contrast, the amount of 1α,25(OH)2D3 remained the same after incubation with hepatic microsomes from prednisone- or vehicle-treated mice (Fig. 3).

**Kinetic Analysis of 1α,25(OH)2D3 Metabolism.** Kinetic analysis of metabolite formation from 1α,25(OH)2D3 was performed in pooled MLM and HLM over a range of substrate concentrations (2–40 μM). The metabolite formation data were fit to either the Michaelis-Menten or Hill equation, and kinetic parameters of 1α,25(OH)2D3 metabolites are shown in Table 1. To compare the metabolic efficiency of microsomes prepared from vehicle-, prednisone-, or dexamethasone-treated mice, the rates of formation of the M1 and M2 were examined. The Vₘₐₓ value for M2 formation was significantly higher in dexamethasone-treated mice and marginally increased in prednisone-treated mice compared with vehicle-treated mice (Table 1). In dexamethasone-treated mice, Kₘ values for M1, M2, and M4 formation are low and comparable, which indicates that these products are predominantly formed at lower concentrations of 1α,25(OH)2D3. M4, the most abundant metabolite formed in HLM, has the lowest Kₘ value (7.6 ± 0.2 μM). This suggests that even at lower concentrations of 1α,25(OH)2D3, formation of M4 will be preferred. Due to lack of availability of authentic standards, Vₘₐₓ values for M3, M4, and M5 could not be determined.

**P450 Chemical Inhibition Studies.** The contribution of individual P450 in 1α,25(OH)2D3 biotransformation was assessed using chemical inhibitors that selectively targeted P450 isoforms. P450 inhibition studies were performed using pooled hepatic microsomes prepared

---

**Fig. 1.** Representative LC/MS chromatogram that shows hydroxylated metabolites [(M+NH₄)⁺, m/z 450] of 1α,25(OH)2D3 after biotransformation in MLM (0.15 mg/ml) and HLM (0.25 mg/ml) and in human rCYP3A4 Supersomes (15 pmol/ml). The chromatograms were obtained from LC/MS analysis of incubations that contained hepatic microsomes, 1α,25(OH)2D3, and NADPH-regenerating system for 30 min at 37°C. A, hydroxylated metabolites of 1α,25(OH)2D3 in HLM and human recombinant CYP3A4 Supersomes.
We used nine inhibitors of P450 enzymes: ketoconazole (CYP3A), SKF 525A (broad spectrum P450 inhibitor), furafylline (CYP1A2), α-naphthoflavone (CYP1A1), sulfaphenazole (CYP2C), quinine (CYP2D), diethyldithiocarbamate (CYP2E), 8-methoxypsoralen (CYP2A), and orphenadrine (CYP2B). The results of the chemical inhibition studies showed that ketoconazole at 1 μM inhibited the formation of hydroxy metabolites of 1α,25(OH)2D3 by ~90 to 100% in MLM (Fig. 4). Comparable inhibition was achieved after incubation with broad-spectrum P450 inhibitor SKF 525A. Other P450 inhibitors showed little or no inhibition. Ketoconazole-mediated CYP3A inhibition was observed for the formation of M5 in vehicle- or prednisone-treated mice and for M1, M2, and M3 in dexamethasone-treated mice. The inhibitory effect of ketoconazole on 1α,25(OH)2D3 biotransformation in MLM was dose-dependent over a concentration range of 0.1 to 10 μM (data not shown).

**Induction of CYP3A Isoforms and Triazolam Hydroxylation Assay.** CYP3A protein levels and marker activity were measured in individual mouse hepatic microsomes. Hepatic CYP3A protein levels were significantly increased after intraperitoneal treatment of adult male CD-1 mice with dexamethasone. An antibody against mouse CYP3A isoforms (CYP3A11, CYP3A16, CYP3A41, CYP3A44, and CYP3A25) was used to detect two protein bands in the immunoblot. The upper band, which was detected in control and treated samples, was used to determine the relative CYP3A protein level. Relative CYP3A protein levels were increased by approximately 53- and 2-fold in liver microsomes from dexamethasone- and prednisone-treated mice, respectively, compared with the vehicle-treated group (Fig. 5A). Likewise, the formation of 1'-hydroxy triazolam and 4-hydroxy triazolam from triazolam, a CYP3A marker activity, was markedly increased in hepatic microsomes from dexamethasone-treated mice, compared with vehicle-treated and prednisone-treated mice (Fig. 5B).

**In Vitro Inhibition of 1α,25(OH)2D3 Catabolism by Drug Interactions.** Pooled HLM were coincubated with 1α,25(OH)2D3 and the drugs listed below to evaluate their inhibitory potential to cause vitamin D3-drug interactions. Drugs used in the present study were those used as anticancer agents (ketoconazole, tamoxifen, docetaxel, and paclitaxel), antivirals (ritonavir), and anti-infectives (clarithromycin, chloramphenicol, troleandomycin). Results from the initial single concentration study suggest that ketoconazole (1 μM), docetaxel (1.24 μM), and ritonavir (10 μM) are the strongest inhibitors of 1α,25(OH)2D3 catabolism, showing ~95 to 100% inhibition (Fig. 6, A and B). Other drugs used in our study inhibited the formation of hydroxy metabolites by ~40 to 90%. The inhibitory effect of these drugs was further characterized by determining IC50 values using nonlinear regression analysis. A summary of IC50 values for the formation of all four metabolites of 1α,25(OH)2D3 in HLM are shown in Table 2. Analysis of IC50 values indicates that ritonavir is the most potent inhibitor of M1 to M4 metabolite formation, followed by ketoconazole and docetaxel. Similar inhibitory effects of these drugs...
were also observed on triazolam hydroxylation in HLM (Fig. 6C) and human rCYP3A4 (data not shown).

**Discussion**

1α,25(OH)₂D₃, the active metabolite and the most potent natural analog of vitamin D₃, is an autocrine and paracrine regulator of multiple physiological functions, which include maintenance of calcium and phosphate levels, bone mineralization, cell proliferation and differentiation, inflammation, and immunity (Holick, 2005). Thus, 1α,25(OH)₂D₃ is a potential candidate for the treatment and prevention of diseases such as rickets/osteomalacia, cancer, and immune disorders (e.g., autoimmune diseases, AIDS-related opportunistic infections). Typically, in mammals, P450-mediated oxidative metabolism of 1α,25(OH)₂D₃ is considered as a vital step in its deactivation (Prosser and Jones, 2004). Although CYP24A1-mediated renal metabolism of 1α,25(OH)₂D₃ is well studied, hepatic biotransformation of 1α,25(OH)₂D₃ in humans and rodents is not well characterized. In the present study, we investigated the microsomal biotransformation of 1α,25(OH)₂D₃ in MLM and HLM and in human rCYP3A4, and we determined the effects of commonly used drugs on the CYP3A-mediated metabolism of 1α,25(OH)₂D₃.

The results from our study show that 1α,25(OH)₂D₃ was metabolized to four metabolites in HLM and rCYP3A4 Supersomes (Fig. 7).
In contrast, in untreated MLM, there was only one major metabolite unique from the ones found in humans, as was determined by LC/MS. However, the metabolite formation pattern in hepatic microsomes from dexamethasone-treated mice was comparable with that of HLM and rCYP3A4 Supersomes. Metabolites M1 and M2 corresponded to 1α,23S,25(OH)2D3 and 1α,24R,25(OH)2D3 (M2), respectively. Based on the chromatographic and MS properties as well as literature reports, it is likely that metabolite M3 is 1α,24S,25(OH)2D3 and M4 is 1α,23R,25(OH)2D3. Gupta et al. (2004, 2005) showed that 24- and 25-hydroxylation of 1α(OH)D3, a clinically important analog of vitamin D3, are catalyzed by CYP3A4 in a stereospecific manner. In kidney, CYP24A1-mediated metabolism of 1α,25(OH)2D3 yields both C-23- and C-24-hydroxylated products. From both careful examination of relative retention time and observation of additional multiple reaction monitoring transitions, it is clear that M3 and M5 are two different metabolites with the same molecular weight. Although the chemical identity of the metabolite M5 of 1α,25(OH)2D3 could not be determined, potential candidates include a hydroxylation product of the aliphatic side chain at C-22 or hydroxylation of methyl group at C-21. For example, rCYP3A4 hydroxylates at the C-22 position of ursodeoxycholic acid, a steroidal structure with aliphatic side chain (Bodin et al., 2005).

Relative contributions of individual P450 enzymes to the hepatic biotransformation of 1α,25(OH)2D3 in mice was studied using a panel of selective P450 chemical inhibitors. Ketoconazole, used at low concentrations selective for CYP3A isoforms (Baldwin et al., 1995), inhibited the formation of all the five metabolites in MLM and HLM. It appears that metabolites M1 to M4 emerged at the expense of M5 after treatment with dexamethasone. Because there are six different CYP3A isoforms (CYP3A11, CYP3A13, CYP3A16, CYP3A25, CYP3A41, and CYP3A44) expressed in MLM, it is plausible that treatment with dexamethasone led to induction of isoforms, which predominantly catalyze the formation of M1 to M4 but not M5. In addition, identical metabolic profiles in rCYP3A4 Supersomes and HLM indicate that CYP3A isoforms are primarily responsible for the hepatic microsomal biotransformation of 1α,25(OH)2D3. Previously, it has been shown that mitochondrial CYP24A1 is one of the major enzymes involved in the biotransformation of 1α,25(OH)2D3 in kidney (Prosser and Jones, 2004); however, this does not apply to the liver and intestine. CYP3A4 enzyme constitutes approximately 40 and 80% of the total P450 enzymes in human liver and intestine, respectively (Paine et al., 2006), whereas mitochondrial CYP24A1 has low or undetectable hepatic and intestinal expression in humans and rodents (Komuro et al., 1999; Cheng et al., 2003; Xu et al., 2006). In contrast to CYP3A, mitochondrial CYP24A1 is also less inducible by therapeutic or environmental agents (Zhou et al., 2006), and not many potent inhibitors are known. Thus, based on relative abundance of CYP24A1 and CYP3A4 in human liver and their induction or inhibition potential, it is unlikely that CYP24A1 has any significant role in the hepatic biotransformation of 1α,25(OH)2D3.

Metabolite formation pattern in our study is similar to the one report we found of 1α,25(OH)2D3, biotransformation in HLM (Xu et al., 2006), which also concluded that hepatic metabolism of
Fig. 4. Effect of chemical inhibitors on biotransformation of 1α,25(OH)₂D₃ in pooled hepatic microsomes from vehicle- (A), dexamethasone- (B), and prednisone-treated (C) mice. Metabolite formation was measured after pre-incubation of individual inhibitors with microsomes followed by 30-min incubation of 1α,25(OH)₂D₃ (20 μM) at 37°C, as described under Materials and Methods. Results are expressed as mean (% of control activity) ± S.D. of three different incubations. Control activity was measured in the presence of vehicle (methanol) without any inhibitor. Differences between treatment groups were compared using one-way analysis of variance (parametric), followed by the Student Newman Keuls multiple comparison test. *, significantly different from the microsomes incubated with methanol (vehicle control) with $P < 0.05$. 

A

B

C

\[ \text{Hydroxy metabolite formation} \]
1α,25(OH)₂D₃ in human liver is catalyzed by CYP3A4. We also found that human microsomal CYP3A4 hydroxylates 1α,25(OH)₂D₃ at C-23 position in the formation of 1α,23S,25(OH)₂D₃ (M1). However, unlike Xu et al. (2006), we identified 1α,24R,25(OH)₃D₃ (M2) as an additional product of 1α,25(OH)₂D₃ biotransformation after incubation with HLM. Rigorous analyses of the chromatograms from the Xu et al. (2006) study suggest that 1α,24S,25(OH)₂D₃ had also been produced in their incubations, albeit at a much lower extent than we observed, and appeared as a shouldering peak to the adjacent 1α,24S,25(OH)₂D₃ peak. Possible explanations for the differences observed in the metabolite profiles and proportions could be incubation conditions (e.g., incubation time, amount of protein) and analytical methodologies (e.g., chromatographic and MS conditions). A species-based difference was also identified between CYP3A-mediated hepatic metabolism of 1α,25(OH)₂D₃ in humans and mice. In humans, M4 was the major metabolite, whereas M1, M2, M3, and M5 were the major metabolites in mice. Likewise, CYP24A1-mediated metabolism of 1α,25(OH)₂D₃ has been reported to be species-specific. In humans, both the C-23 and C-24 oxidation pathways are present (Beckman et al., 1996). However, rat and mouse CYP24A1 enzymes show a remarkable preference for C-24 to C-23 hydroxylation (Sakaki et al., 1999, 2000). To our knowledge, this is the first
FIG. 6. Blockade of 1α,25(OH)2D3 catabolism in HLM in vitro by commonly used drugs. Metabolite formation was measured (A–C) after preincubation of individual drugs with hepatic microsomes (0.25 mg/ml) followed by 30-min incubation of 1α,25(OH)2D3 (20 μM) at 37°C, as described under Materials and Methods. Results are expressed as mean (activity) ± S.D. of three different incubations. Control activity was measured in the presence of vehicle (methanol) without any drug. Differences between treatment groups were compared using one-way analysis of variance (parametric), followed by the Student Newman Keuls multiple comparison test. *, significantly different from the microsomes incubated with methanol (vehicle control) with P < 0.05.
study of 1α,25(OH)₂D₃ biotransformation that identifies the P450 enzymes involved in MLM.

The effects of commonly used medications on the biotransformation of 1α,25(OH)₂D₃ have not previously been explored experimentally. Dexamethasone and prednisone are both clinically important drugs commonly used in cancer treatment regimens and as anti-inflammatory and immunosuppressant agents (Czock et al., 2005; Beer et al., 2007; Inaba and Pui, 2010). Results from our study have shown that administration of dexamethasone, but not prednisone, can greatly increase breakdown of 1α,25(OH)₂D₃ by CYP3A isoforms in mice, which could potentially lead to diminished biological effects of vitamin D₃. Although both dexamethasone and prednisone are harmful to bone health, our results could possibly explain the lower incidences of bone disorders after exposure to prednisone (Inaba and Pui, 2010). In contrast, drugs used to treat cancer (e.g., tamoxifen, taxanes), infectious diseases (e.g., clarithromycin, chloramphenicol), and AIDS (e.g., ritonavir) blocked the hepatic catabolism of the active vitamin D₃ metabolite in vitro, potentially leading to additional therapeutic benefits and maintenance of bone health. Ketoconazole, a drug commonly used in fungal infections and in prostate cancer, potently inhibited 1α,25(OH)₂D₃ biotransformation in HLM. It has been previously observed that oral administration of 200 mg of ketoconazole in healthy subjects leads to a peak plasma concentration of 4.5 to 7.5 µM (Heel et al., 1982; Gupta et al., 1994). Likewise, a single dose of ritonavir (600 mg) produced a peak plasma level of 13.1 µg/ml or 18 µM in healthy volunteers (Ouellet et al., 1998). Likewise, anti-infective agents (clarithromycin, chloramphenicol) and anticancer agents (taxanes and tamoxifen) were able to inhibit the CYP3A4-mediated metabolism of 1α,25(OH)₂D₃. Thus, blockade of 1α,25(OH)₂D₃ catabolism by these drugs can potentially enhance their therapeutic benefits by exacerbating the inherent anticancer and immunomodulatory effects of 1α,25(OH)₂D₃ in patients who have cancer or AIDS.

Dexamethasone induces P450 expression in human and mouse liver via involvement of nuclear receptors such as the pregnane X receptor (PXR) and glucocorticoid receptor (Rushmore and Kong, 2002). Although prednisone is a glucocorticoid receptor (but not PXR) agonist, there is no report of prednisone-mediated regulation of CYP3A enzymes. This could explain the differential effects of the two glucocorticoids. Moreover, Hashizume et al. (2008) have shown that PXR-regulated UGT1A isoforms are involved in the conjugation of 1α,25(OH)₂D₃ in human liver, which can also alter the 1α,25(OH)₂D₃ pathways of conjugated metabolites.

### Table 2

<table>
<thead>
<tr>
<th>Inhibitors</th>
<th>M1 (µM)</th>
<th>M2 (µM)</th>
<th>M3 (µM)</th>
<th>M4 (µM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ritonavir*</td>
<td>0.013 (0.001–0.154)</td>
<td>0.028 (0.003–0.227)</td>
<td>0.008 (0.000–0.113)</td>
<td>0.016 (0.002–0.151)</td>
</tr>
<tr>
<td>Ketoconazole*</td>
<td>0.040 (0.024–0.065)</td>
<td>0.042 (0.027–0.067)</td>
<td>0.565 (0.162–1.971)</td>
<td>0.032 (0.021–0.050)</td>
</tr>
<tr>
<td>Clarithromycin*</td>
<td>&gt;30</td>
<td>&gt;30</td>
<td>&gt;30</td>
<td>&gt;40</td>
</tr>
<tr>
<td>Tamoxifen*</td>
<td>&gt;40</td>
<td>&gt;40</td>
<td>&gt;40</td>
<td>&gt;40</td>
</tr>
<tr>
<td>Docetaxel*</td>
<td>0.038 (0.007–0.203)</td>
<td>0.077 (0.018–0.338)</td>
<td>0.012</td>
<td>0.038 (0.012–0.120)</td>
</tr>
</tbody>
</table>

*Values represent means (95% confidence interval) of triplicate determinations.
CYP3A isoforms were determined to have a major role in the hepatic affect biotransformation of CYP3A substrates. Another point of consideration is that 1α,25(OH)2D3 also acts as an endogenous regulator of VDR-mediated CYP3A4 expression and therefore may have a role in its own homeostasis and could potentially affect biotransformation of CYP3A substrates.

In summary, this is the first report of hepatic biotransformation of 1α,25(OH)2D3 in mice. Species differences between metabolite profiles derived from mouse and human liver microsomes were observed in the biotransformation of 1α,25(OH)2D3. In the present study, CYP3A isoforms were determined to have a major role in the hepatic biotransformation of 1α,25(OH)2D3 in both species. In addition, this is the first experimental report of stimulation or blockade of 1α,25(OH)2D3 biotransformation in liver by therapeutic drugs. Deoxymethasone, but not prednisone, augments CYP3A-mediated catabolism of 1α,25(OH)2D3 in mice. In contrast, medications, which are commonly used to treat cancer and AIDS patients, could lead to blockade of active vitamin D3 catabolism. Overall, therefore, it is reasonable to deduce that treatment regimens used for patients with cancer, AIDS, and inflammatory diseases could affect vitamin D homeostasis.

Acknowledgments
We thank Dr. Toshiyuki Sakaki (Toyama Prefectural University, Toyama, Japan) for generously providing the authentic standards of 1α,24R,25(OH)2D3 and 1α,23S,25(OH)2D3.

Authorship Contributions
Conducted experiments: Deb and Guns.
Contributed new reagents or analytic tools: Deb and Adomat.
Performed data analysis: Deb.

References